Adriaensen Gwijde F J P M, Lim Keng-Hua, Fokkens Wytske J
Department of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Department of Otorhinolaryngology, Tan Tock Seng Hospital, Singapore.
Int Forum Allergy Rhinol. 2017 Aug;7(8):813-820. doi: 10.1002/alr.21963. Epub 2017 May 30.
Postoperative wound healing after endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis (CRS) is an important factor in procedural success. Local steroids and separation of opposing mucosa are commonly implemented to optimize healing. A bioabsorbable, fluticasone propionate (FP)-eluting implant, SinuBand FP, was assessed for its safety and efficacy when used in patients with CRS and nasal polyps, who were indicated for ESS including bilateral anterior and posterior ethmoidectomy.
A first-in-human, randomized, partially double-blind, single-tertiary-referral-center, controlled trial enrolling 30 patients receiving 2 of 3 treatments (1 per sinus, intrapatient control): SinuBand FP, SinuBand (without FP), or standard nasal pack (Merocel®). Primary outcome measures were local safety, ocular safety (intraocular pressure [IOP], lens opacity), and 24-hour urine cortisol. Secondary measures (evaluated by independent review of postoperative video endoscopies) were ethmoid inflammation, polyp score, adhesion formation, and Lund-Kennedy score. Patient-reported outcomes of postoperative pain, nasal congestion, and nasal discharge were collected.
Of 30 enrolled patients (used for safety analysis), 27 patients completed the trial. SinuBand FP showed local safety, ocular safety, and no significant change in 24-hour urine cortisol. SinuBand FP showed a trend to do better concerning inflammation. Concerning polyp score SinuBand FP did significantly better compared to Merocel (p = 0.03). No significance compared to SinuBand without corticosteroids (p = 0.97). Adhesions were comparable across treatments. Patient reported pain was nominally lower in the SinuBand group.
SinuBand FP was well tolerated and showed evidence of efficacy. A larger study is needed to further evaluate and confirm the benefits of SinuBand FP.
慢性鼻窦炎(CRS)患者接受鼻内镜鼻窦手术(ESS)后的伤口愈合是手术成功的重要因素。通常采用局部类固醇和分离相对的黏膜来优化愈合。一种可生物吸收的、释放丙酸氟替卡松(FP)的植入物SinuBand FP,在被推荐进行包括双侧前后筛窦切除术在内的ESS的CRS和鼻息肉患者中,对其安全性和有效性进行了评估。
一项首次人体、随机、部分双盲、单三级转诊中心的对照试验,招募了30名接受三种治疗中的两种(每个鼻窦一种,患者内对照)的患者:SinuBand FP、SinuBand(不含FP)或标准鼻填塞物(Merocel®)。主要结局指标为局部安全性、眼部安全性(眼压[IOP]、晶状体混浊)和24小时尿皮质醇。次要指标(通过对术后视频内镜检查的独立评估)为筛窦炎症、息肉评分、粘连形成和Lund-Kennedy评分。收集患者报告的术后疼痛、鼻塞和鼻分泌物的结局。
在30名入组患者(用于安全性分析)中,27名患者完成了试验。SinuBand FP显示出局部安全性、眼部安全性,且24小时尿皮质醇无显著变化。SinuBand FP在炎症方面有改善趋势。在息肉评分方面,SinuBand FP与Merocel相比有显著改善(p = 0.03)。与不含皮质类固醇的SinuBand相比无显著差异(p = 0.97)。各治疗组的粘连情况相当。患者报告SinuBand组的疼痛名义上较低。
SinuBand FP耐受性良好且显示出疗效证据。需要进行更大规模的研究来进一步评估和确认SinuBand FP的益处。